TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced today that it has entered into an option agreement granting leading global eye health company Bausch + Lomb the right to acquire the company. This strategic move aligns with a shared goal of advancing groundbreaking treatments addressing unmet medical needs in ophthalmology. InflammX’s pipelin ...

Bausch Health Companies (NYSE: BHC , TSX: BHC:CA ) is one of the undervalued stocks currently, trading only at trailing EV/EBITDA of 8.03x. The expected complete spin-off of its Bausch + Lomb ( BLCO ) will have more benefitHi there! I am an equity research analyst by profession but a trader by heart, with a background in accounting. I try my best to be a responsible investor, guided by my expertise in fundamental and technical analysis. I enjoy surfing and riding the trends about equity, currencies and cryp ...

A month has gone by since the last earnings report for Bausch Health (BHC) . Shares have lost about 11.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Bausch due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boo ...

Investors might want to bet on Bausch Health (BHC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing ea ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Bausch Health (BHC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bausch Health is a member of the Medical sector. This group includes 1024 individual stocks and c ...

Shares of Bausch Health Companies Inc. (BHC) gained 12.6% after the company reported better-than-expected third-quarter results on Oct. 30. The company also raised its annual revenue guidance.Adjusted earnings per share of $1.12 beat the Zacks Consensus Estimate of $1.03. The reported figure increased from $1.03 in the year-ago quarter due to higher revenues.Total revenues of $2.5 billion were up 12% year over year. The top line also beat the Zacks Consensus Estimate of $2.4 billion.Excluding the impact of ...

For the quarter ended September 2024, Bausch Health (BHC) reported revenue of $2.51 billion, up 12.2% over the same period last year. EPS came in at $1.12, compared to $1.03 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $2.43 billion, representing a surprise of +3.33%. The company delivered an EPS surprise of +8.74%, with the consensus EPS estimate being $1.03. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Bausch Health (BHC) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.74%. A quarter ago, it was expected that this drugmaker would post earnings of $0.89 per share when it actually produced earnings of $0.89, delivering no surprise. Over the last four quarters, the company has surpa ...

| --- | --- | --- | --- | --- | --- | --- | |------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | 3Q 2024 | | | | | | | | EARNINGS | | | | | | | | OCTOBER 30, 2024 | | | | | | | | | | | | | | | 1 Forward-Looking Statements; Non-GAAP Information Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limite ...

Financial Data and Key Metrics Changes - Revenues for Bausch Health, excluding Bausch + Lomb, increased by 7% on a reported basis and 8% on an organic basis compared to Q3 2023 [5][6] - Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, increased by approximately 9% compared to the prior year period [6][21] - Adjusted cash flow from operations was $343 million, a 75% increase versus the same period a year ago [18] Business Line Data and Key Metrics Changes - Salix segment revenues increased by 5% year-over-year, with XIFAXAN driving most of the revenue growth [22] - International segment revenues were $291 million, an increase of 6% on a reported basis and 8% on an organic basis [23] - Solta Medical segment revenues were $112 million, reflecting a 35% increase year-over-year [24] - Diversified segment revenues were $269 million, an increase of 4% on a reported basis and 7% on an organic basis [25] Market Data and Key Metrics Changes - Strong consumer demand was noted in South Korea, driven by direct-to-consumer marketing investments [9] - In Canada, growth was particularly strong in promoted portfolio products, including Contrave, which achieved double-digit growth [8] Company Strategy and Development Direction - The company is focused on sustained growth and innovation, with significant strides made in meeting 2024 objectives [6][9] - The Red Sea program aims to address unmet needs in cirrhotic patients, with ongoing studies and a focus on operational innovation [10][11] - The full separation of Bausch + Lomb remains a strategic priority, with ongoing evaluations to maximize value [16][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to generate value from its portfolio and emphasized the importance of operational excellence [30][31] - The company is optimistic about growth opportunities in various segments, including Salix and Solta, and is focused on capitalizing on market demands [41][44] Other Important Information - The company reduced its net debt by approximately $110 million in Q3, with a year-to-date reduction of $555 million [26] - Adjusted gross margin for Bausch Health, excluding Bausch + Lomb, was 82.5%, reflecting favorable net pricing [19] Q&A Session All Questions and Answers Question: Status of XIFAXAN legal disputes - Management stated that Norwich cannot launch a generic until 2029 and emphasized the intention to vigorously defend XIFAXAN's intellectual property [34] Question: Potential dividend considerations - The company will prioritize meeting debt obligations and reinvesting in the business before considering any return to shareholders [52] Question: Addressing cost structure post-XIFAXAN exclusivity - Management indicated a focus on a fit-for-purpose model to manage costs and invest in growth opportunities, particularly in international markets [56][58] Question: Timing of XIFAXAN exclusivity expiration - Management confirmed confidence in defending patents until January 1, 2028, while acknowledging the presence of first filer status by Teva [62] Question: Insights from site visits - Management highlighted the excitement and energy among teams globally, with a focus on business development and growth opportunities [45][46] Question: Rationale for Red Sea program target population - The program aims to address a significant unmet need in cirrhotic patients, with a focus on preventing decompensation [67]